Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Makes Big Strides In Eradicating Sleeping Sickness

Acoziborole Cured 95% of People With Late-Stage Disease

Executive Summary

The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.

You may also be interested in...



Sanofi Puts Faith In Rare Review Procedure For ‘Breakthrough’ Sleeping Sickness Drug

Sanofi believes its fully oral sleeping sickness treatment, fexinidazole, will support efforts to eliminate the disease by 2020. The European Medicines Agency is set to start reviewing the product soon with a view to it being used in Africa.

Novartis CEO Laments Europe’s Anti-Innovation Atmosphere

Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.

AlzeCure Confident Of Bagging Partner For Pain Drug

The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel